Biohaven Pharmaceutical Valuation
| BHVN Stock | USD 46.38 0.90 1.90% |
At this time, the firm appears to be overvalued. Biohaven Pharmaceutical shows a prevailing Real Value of $36.9 per share. The current price of the firm is $46.38. Our model approximates the value of Biohaven Pharmaceutical from analyzing the firm fundamentals such as Shares Owned By Insiders of 11.15 %, return on equity of -2.65, and Current Valuation of 4.34 B as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Biohaven Pharmaceutical's valuation include:
Price Book 14.8416 | Enterprise Value 4.3 B | Enterprise Value Ebitda (2.19) |
Overvalued
Today
Please note that Biohaven Pharmaceutical's price fluctuation is very steady at this time. Calculation of the real value of Biohaven Pharmaceutical is based on 3 months time horizon. Increasing Biohaven Pharmaceutical's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Biohaven Pharmaceutical is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Biohaven Stock. However, Biohaven Pharmaceutical's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 46.38 | Real 36.9 | Target 28.2 | Hype 46.57 |
The intrinsic value of Biohaven Pharmaceutical's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Biohaven Pharmaceutical's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Biohaven Pharmaceutical Holding helps investors to forecast how Biohaven stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Biohaven Pharmaceutical more accurately as focusing exclusively on Biohaven Pharmaceutical's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Biohaven Pharmaceutical's intrinsic value based on its ongoing forecasts of Biohaven Pharmaceutical's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Biohaven Pharmaceutical's closest peers.
Biohaven Pharmaceutical Cash |
|
Biohaven Valuation Trend
Knowing Biohaven Pharmaceutical's actual value is paramount for traders when making sound investment determinations. Using both Biohaven Pharmaceutical's enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Biohaven Pharmaceutical Total Value Analysis
Biohaven Pharmaceutical Holding is currently anticipated to have valuation of 4.34 B with market capitalization of 4.69 B, debt of 30.88 M, and cash on hands of 23.21 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Biohaven Pharmaceutical fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
4.34 B | 4.69 B | 30.88 M | 23.21 M |
Biohaven Pharmaceutical Asset Utilization
One of the ways to look at asset utilization of Biohaven is to check how much profit was generated for every dollar of assets it reports. Biohaven Pharmaceutical Holding shows a negative utilization of assets of -1.19 percent, losing $0.0119 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Biohaven Pharmaceutical Holding shows how discouraging it operates for each dollar spent on its assets.Biohaven Pharmaceutical Ownership Allocation
Biohaven Pharmaceutical holds a total of 101.12 Million outstanding shares. The majority of Biohaven Pharmaceutical Holding outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Biohaven Pharmaceutical to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Biohaven Pharmaceutical. Please pay attention to any change in the institutional holdings of Biohaven Pharmaceutical Holding as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Biohaven Pharmaceutical Profitability Analysis
Net Loss for the year was (408.17 M) with profit before overhead, payroll, taxes, and interest of 0.About Biohaven Pharmaceutical Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Biohaven Pharmaceutical Holding. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Biohaven Pharmaceutical based exclusively on its fundamental and basic technical indicators. By analyzing Biohaven Pharmaceutical's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Biohaven Pharmaceutical's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Biohaven Pharmaceutical. We calculate exposure to Biohaven Pharmaceutical's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Biohaven Pharmaceutical's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -3.4 M | -3.2 M | |
| Pretax Profit Margin | (0.41) | (0.43) | |
| Operating Profit Margin | (0.43) | (0.45) | |
| Net Loss | (0.42) | (0.44) | |
| Gross Profit Margin | 0.72 | 0.64 |
Biohaven Pharmaceutical Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 71.2 M |
Biohaven Pharmaceutical Current Valuation Indicators
Biohaven Pharmaceutical's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Biohaven Pharmaceutical's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Biohaven Pharmaceutical, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Biohaven Pharmaceutical's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Biohaven Pharmaceutical's worth.When determining whether Biohaven Pharmaceutical offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biohaven Pharmaceutical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biohaven Pharmaceutical Holding Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biohaven Pharmaceutical Holding Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biohaven Pharmaceutical Holding. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biohaven Pharmaceutical. If investors know Biohaven will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biohaven Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (9.37) | Return On Assets (1.19) | Return On Equity (2.65) |
The market value of Biohaven Pharmaceutical is measured differently than its book value, which is the value of Biohaven that is recorded on the company's balance sheet. Investors also form their own opinion of Biohaven Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biohaven Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biohaven Pharmaceutical's market value can be influenced by many factors that don't directly affect Biohaven Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biohaven Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biohaven Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biohaven Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.